Vancouver-based Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and an expansive lipid ...

Our medical tools and techniques are rapidly improving but our system for delivering health care is a source of widespread ...

Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path Hold ...

HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop ...

STONY BROOK, NY / ACCESSWIRE / / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of the buildout of ...

Maravai Lifesciences Holdings, Inc. (Maravai) has announced its preliminary unaudited 2024 revenue, expecting to report total ...

Creative Diagnostics, a reagent supplier and developer focused on biologics quality control, has announced the launch of its new Viral Nucleic Acid Residue Assay Kits (qPCR) to ensure the purity and ...

With years of experience in the pharmaceutical and life science sectors, CD Bioparticles announces the launch of its new line of Endotoxin Free Silver Nanoparticles for biomedical research and ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

The Company also announced that it plans to announce its fourth quarter and full year 2024 financial and operating results after the market closes on Tuesday, February 25, 2025, and will host a ...

Maravai LifeSciences Holdings said Wednesday it expects to report full-year revenue for 2024 near the midpoint of its most recent outlook. The San Diego company has guided for full-year revenue ...